Cost of opioid medication abuse with and without tampering in the USA

Jeffrey Vietri¹
Elizabeth T Masters²
Alexandra I Barsdorf²
Jack Mardekian³

1Health Outcomes Practice, Kantar Health, Horsham, PA, USA; 2Health Economics & Outcomes Research, Pfizer Inc., New York, NY, USA; 3Statistical Research & Data Science Center, Pfizer Inc., New York, NY, USA

Objective: To provide per-patient estimates of the economic burden for opioid medication abuse with and without tampering.

Patients and methods: Adults in the US who participated in the 2010 and/or 2011 National Health and Wellness Survey were resurveyed to provide information on use and abuse of prescription opioids in the previous 3 months. Participants (N=20,885) were categorized as those who abused and tampered (n=107), abused without tampering (n=118), those who reported using of opioids as prescribed (n=981), and non-opioid controls (n=19,679). Average wages from the Bureau of Labor Statistics and health care unit costs from the Truven MarketScan database were applied to self-reported work impairment (absenteeism, presenteeism, and overall work impairment) and health care resource utilization (health care provider visits, emergency room visits, hospitalizations, and drug rehabilitation) to estimate indirect and direct medical costs, respectively. Estimated mean costs for these groups were compared using analysis of variance, and generalized linear models were used to compare costs adjusted for confounders.

Results: Those who abused and tampered had significantly higher mean indirect (work impairment: $3,614 vs $2,938, p<0.001) and direct (health care use: $23,328 vs $4,514, p<0.001) costs over 3 months than those who abused without tampering. This included higher mean incremental costs for non-opioid-related medical visits ($14,180 vs $2,236, p<0.001), opioid-related medical visits ($8,790 vs $2,223, p<0.001), and drug rehabilitation ($358 vs $55, p<0.001). Increased total direct costs were associated with tampering after adjusting for confounders (p<0.001). Median incremental costs were also higher among those who tampered.

Conclusion: Tampering with prescription opioid medications is associated with significantly increased medical costs compared to abuse without tampering. Reducing tampering may provide net health care savings.

Keywords: direct costs, health care resource utilization, indirect costs, medication tampering, opioid abuse, work impairment, abuse deterrent

Introduction

Prescription opioid medications are highly effective pain relievers, with a long-established role in the management of acute pain and moderate-to-severe chronic pain.¹ Many individuals use opioids solely for their intended purpose. However, abuse of prescription opioid medications remains a widespread problem in the USA, with the abuse of prescription and illicit opioids officially declared a Nationwide Public Health Emergency.² Non-medical use (NMU) of opioids – taking more than the prescribed dose of one’s own medication, taking a medication prescribed for another individual, and/or misusing or abusing a medication – is estimated at 11.1
million Americans each year. US societal costs attributable to prescription opioid NMU were estimated to be as high as $55.7 billion in 2007. Chronic NMU of prescription pain medications increased by 74.6% from 2002–2003 to 2009–2010. Thousands of overdose deaths are attributed to prescription opioids each year, with mortality quadrupling from 1999 to 2010. Drug treatment admissions related to prescription opioids increased more than five-fold between 1998 and 2008, and emergency room (ER) visits related to prescription opioids increased by 183% from 2004 to 2011. These trends have spurred the development of guidelines with the aim to better control the prescription of opioids.

One type of NMU is abuse, which we consider as use to obtain psychotrophic effects, or more colloquially, “to get high”. Individuals may tamper with medication to facilitate abuse. Major forms of tampering include ingestion (ie, chewing and swallowing), inhalation, injection, and smoking, with other methods being less prevalent. Vietri et al reported the prevalence of prescription opioid abuse during the previous 3 months among US adults to be 1.31%, with approximately half (0.67%) tampering during that time. Numerous routes of abuse were reported, though drugs were most commonly abused in their original form. In general, opioid abusers, and especially those who tamper with opioid medications, have much worse health outcomes than those who do not abuse or tamper with opioid medications. Unintended routes of abuse are associated with risks over and above those due to overconsumption of the medication, such as the increased risk of contracting HIV and other blood-borne illnesses in those who inject opioids with non-sterile needles.

There are clear economic costs to consider, alongside the humanistic impact, including extensive workplace costs, health care costs, and criminal justice costs. In a 2014 review of the US economic burden of opioid abuse, mean annual excess health care costs for opioid abusers with private insurance ranged from $14,054 to $20,546 and from $5,874 to $15,183 for opioid abusers with Medicaid, when compared with control subjects. The US national estimate for presenteeism to work productivity and more frequent use of health care in US adults, compared with those who do not abuse or tamper with opioid medications. While these findings indicate the existence of an economic burden associated with prescription opioid tampering, the economic costs, including incremental costs, have not been presented in the literature. In this context, the objective of this study is to provide patient estimates of the economic burden of opioid medication abuse with and without tampering among US adults due to work impairment and health care resource use.

**Patients and methods**

**Data source**

The current study used the online survey previously described by Vietri et al. The design was a cross-sectional study administered among recent (in the past 3 months) users of prescription opioid medication in the US general population. These respondents were identified through screening of participants from the National Health and Wellness Survey (NHWS). The NHWS also provided data on work productivity and activity impairment (WPAI) and health care resource use from control individuals who indicated no use of opioids. The survey received approval from the Essex Institutional Review Board (Lebanon, NJ, USA). All respondents provided written informed consent prior to taking part; the consent form was administered online, with participants clicking a link to indicate their agreement to participate.

A total of 55,223 potential respondents from the 2010 and 2011 NHWS were invited to participate, and 25,864 respondents were screened for use of opioid medications in the previous 3 months. Specifically, they were then asked to reflect on any medications taken in the past 3 months, regardless of whether these medications were prescribed to them. The survey indicated that prescription opioid medications were the focus of the study, and provided a description of opioids and their use in pain. Respondents were then presented with a list of prescription opioid medications and asked to indicate which, if any, they had taken in the past 3 months. The list included both generic and brand names for each opioid followed by a note saying they may also be called by street names, and the street names for each drug were listed. A follow-up question asked respondents to indicate whether each opioid medication had been taken for pain and whether it had been taken “to get high.” These were the only two options provided. Respondents who indicated that they used opioids for pain were subsequently asked if
they had taken their medication according to their doctor’s prescription. Those who indicated taking their medication in a way different from how it was prescribed were considered to have misused their prescription and were not included in the full survey. Otherwise, the respondent was considered to have medical use only.

A total of 1,242 reported either 1) abusing opioid medications (with or without use for pain) or 2) only medical use of opioids as directed, and completed the main opioid-specific questionnaire for this study. Consistent with the previous study using these data, those who provided unintelligible open-ended responses (n=8) or reported tampering with the medication, but did not report abuse (n=28), on this questionnaire were excluded, resulting in a total of 1,206 respondents to the survey. Only responses to the screener questions were collected for respondents who did not self-report use or abuse of prescription opioids. NHWS data were retrieved from the database for all respondents who were screened. Disposition of respondents is presented in Figure 1.

**Measures**

**Opioid abuse**

Abuse was defined by self-reported use of a prescription opioid medication with the intention to get a “high” within the last 3 months.

**Frequency of abuse**

Respondents indicated how often in the previous 3 months they took each medication to get “high” using response options ranging from “less often than 1 day a month” to

---

Figure 1 Disposition of the respondents.

Notes: Figures marked with an asterisk (*) were used to calculate prevalence of prescription opioid abuse, and figures with a dagger (†) were used to calculate the prevalence of tampering in abuse in Vietri et al. Reproduced with permission from Vietri J, Joshi AV, Barsdorf AI, Mardekian J. Prescription opioid abuse and tampering in the United States: results of a self report survey. Pain Med. 2014;15(12):2064–2074, by permission of Oxford University Press.

Abbreviation: NHWS, National Health and Wellness Survey.
“daily”. A distinction between chronic and occasional abusers was made based on reported frequency of use pooled across all opioid drugs. Respondents who reported abusing opioid drugs ≥2 times per week were considered occasional abusers. Respondents abusing >2 times per week were considered chronic abusers, under the rationale that abusing that frequently could not be limited to weekends or days off from a standard school or work week.

**Tampering**

For each medication, respondents indicated whether they took it as received (took it in the form I received it [e.g., swallowed pill, wore patch, placed suppository in rectum, injected it]), and/or whether they took it in a different form (took it in a different form [not as received – e.g., crushed, chewed, injected, infused into vein {intravenous/IV} – not an injection, snorted/ inhaled it, took through rectum, swallowed it with alcohol or any cough/cold medication containing alcohol]). Anyone who indicated that they took it in a form other than prescribed was considered to have tampered with the medication. Follow-up questions asked about which routes were used. Notably, while it could be argued that ingestion of an opioid with alcohol is not tampering, this was not relevant for the present analysis; no respondent was classified as tampering solely based on taking an opioid with alcohol, as all respondents who took an opioid with alcohol also used at least one other route of abuse listed above as tampering.

**Demographic and health characteristics**

The demographic characteristics of respondents included self-reported age, sex, marital status, employment status, health insurance, race, and annual household income, taken from the responses given in the 2011 or 2010 NHWS, linked by a panel ID number that preserved the anonymity of the respondents to the investigators. Information on the general health of the respondents was also taken from NHWS, including current cigarette smoking, alcohol use, exercise, body mass index (calculated from self-reported height and weight), and experience with and physician diagnosis of a variety of medical conditions, which were used to calculate the Charlson Comorbidity Index (CCI).20 as well as alcoholism, psychiatric illness (attention deficit hyperactivity disorder [ADHD], anxiety disorders, depression, bipolar disorder, or schizophrenia), and use of a prescription opioid for pain in the NHWS.

**Work productivity impairment**

These impairments were measured using two versions of the WPAI questionnaire.21 Only respondents who reported being employed full-time, part-time, or self-employed responded to the items measuring work impairment. Activity impairment, which was reported previously,13 was not used in the estimation of costs. All respondents completed the general health version of the WPAI (WPAI:GH) to assess impairment due to health overall, and those who reported using opioids in the past 7 days (the length of the recall period for the instrument) also completed the specific health problem version (WPAI:SHP), pertaining to their use (including abuse) of opioid medications. For those respondents who completed both versions, the higher of the two values for each of the three metrics (absenteeism, presenteeism, and overall work impairment) was used when making comparisons of health-related impairment. To avoid overestimation of overall work impairment, absenteeism and presenteeism were not combined across opioid-specific and general health versions.

**Indirect costs**

Indirect costs were based on productivity loss and were calculated using the 2011 US Department of Labor’s Bureau of Labor Statistics average wages, stratified according to sex and age (18–24, 25–34, 35–44, 45–54, 55–64, and 65 or older).22 For each respondent, an hourly wage rate was estimated by dividing the median weekly income by 40 (the typical number of the hours worked in a week). Next, the number of hours missed in the last week because of one’s health (absenteeism) and the number of hours missed in the last week because of health impairment while at work (presenteeism) were each multiplied by the hourly wage rates to arrive at total lost wages. These weekly costs were then multiplied by 50 (the typical number of work weeks in a year in the USA) to obtain annual estimates of the value of lost productivity. These costs were divided by four to estimate quarterly costs.

**Health care resource use**

Health care resource use was measured as the number of self-reported visits to health care providers, ER visits, and hospitalizations in the last 3 months. Respondents indicated the number of visits of each type specific to use (including abuse) of opioid medications and those unrelated to opioids. Respondents also indicated how many days during the past 3 months they participated in a variety of drug rehabilitation programs, including inpatient rehabilitation, detoxification programs, partial hospitalization programs, replacement therapy (methadone clinics), support groups, individual therapy, and group counseling.
Direct costs

Direct health care costs were estimated from self-reported health care resource use. The 3-month reports of resource use were multiplied by the median cost of each service as reported in the 2011 Truven MarketScan database. The costs applied to opioid-related visits were based on the median cost of opioid abuse coded visits of each type (office, ER, hospital). The International Classification of Disease (ICD-9-CM) codes used were 304.7x (drug dependence involving opioids), 305.5x (opioid abuse), 965.00, 965.02, and 965.09 (poisoning by various opioids/opiates). The costs themselves are presented in Table 1. Unit costs for drug rehabilitation are taken from the Alcohol and Drug Services Study Cost Study (ADSSCS), which were inflated to 2011 dollars using the medical component of the consumer price index, likewise presented in Table 1. Information about the use of non-opioid medications was not included in the survey, and therefore pharmacy costs were not included in the calculations.

Analysis

Costs were compared across those who abused and tampered, those who abused without tampering, respondents reporting medical use only (as directed by their doctor), and the non-opioid using control group from the NHWS using chi-square tests for categorical variables and one-way analysis of variance (ANOVA) for continuous variables. In the case of significant \( p < 0.05 \) results from the ANOVA, pairwise comparisons using Fisher’s least significant difference test were conducted to determine the significance of pairwise differences. No further adjustment for multiplicity was made. Median costs were also calculated, but were not compared using inferential statistics.

Generalized linear models were used to compare the medical costs of individuals who tampered with those who did not, controlling for potential confounders. All-cause direct and indirect costs were compared, as were opioid-specific direct costs. Models used a negative binomial probability distribution and a log-link function. Covariates included age, sex, annual household income >$50k, non-Hispanic white race (y/n), employed (y/n), CCI scores, self-reported psychiatric illness (y/n; includes any self-report of ADHD, depression, anxiety, or schizophrenia), obese BMI (y/n), consumes alcohol (y/n), current smoker (y/n), regular exercise (y/n), use of an opioid in NHWS, and possession of health insurance (y/n). Adjusted means (ie, regression-estimated mean costs equalizing the groups on all covariates) were calculated to facilitate interpretation.

Table 1 Per-service costs applied to each service in estimation of direct medical costs

<table>
<thead>
<tr>
<th>Services</th>
<th>Opioid related</th>
<th>Source</th>
<th>Amount ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical services</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outpatient visit</td>
<td>N</td>
<td>TMS</td>
<td>$108.01</td>
</tr>
<tr>
<td>Outpatient visit</td>
<td>Y</td>
<td>TMS</td>
<td>$116.21</td>
</tr>
<tr>
<td>ER</td>
<td>N</td>
<td>TMS</td>
<td>$552.86</td>
</tr>
<tr>
<td>ER</td>
<td>Y</td>
<td>TMS</td>
<td>$633.11</td>
</tr>
<tr>
<td>Hospitalization</td>
<td>N</td>
<td>TMS</td>
<td>$10,891.64</td>
</tr>
<tr>
<td>Hospitalization</td>
<td>Y</td>
<td>TMS</td>
<td>$5,644.75</td>
</tr>
<tr>
<td>Drug rehabilitation services</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group therapy</td>
<td>Y</td>
<td>ADSSCS</td>
<td>$13</td>
</tr>
<tr>
<td>Individual therapy</td>
<td>Y</td>
<td>ADSSCS</td>
<td>$125</td>
</tr>
<tr>
<td>Partial hospitalization program</td>
<td>Y</td>
<td>ADSSCS</td>
<td>$15</td>
</tr>
<tr>
<td>Detoxification</td>
<td>Y</td>
<td>ADSSCS</td>
<td>$102</td>
</tr>
<tr>
<td>Inpatient rehabilitation</td>
<td>Y</td>
<td>ADSSCS</td>
<td>$102</td>
</tr>
<tr>
<td>Outpatient rehabilitation</td>
<td>Y</td>
<td>ADSSCS</td>
<td>$15</td>
</tr>
<tr>
<td>Methadone</td>
<td>Y</td>
<td>ADSSCS</td>
<td>$17</td>
</tr>
</tbody>
</table>

Note: Values are 2011 dollars.

Abbreviations: ADSSCS, Alcohol and Drug Services Study Cost Study; ER, emergency room; N, no; TMS, Truven MarketScan; Y, yes.

Results

The sample included 107 respondents who abused and tampered, 118 who abused without tampering, 981 reporting medical use of opioids (as directed), and 19,679 respondents who did not report opioid abuse and had their NHWS data included as non-opioid controls. The sociodemographic characteristics of the opioid use groups are presented in Table 2. Most of the characteristics differed across the groups. Comparisons between those who abused and who did not abuse indicated that those who abused opioids were younger, less likely to be white, more likely to be male, smoke cigarettes, and drink alcohol than the rest of the sample (data not shown). Approximately 80% of those who tampered and abused prescription opioids abused them more than twice per week, approximately double the proportion of those who abused but did not tamper.

Indirect costs also varied according to use of prescription opioids, with higher costs among those abusing these medications (Table 3). Absenteeism costs were highest among tampering abusers; at $1,861/quarter these costs were ~12 times the amount of those who did not report any opioid use or abuse (ie, non-opioid controls) and ~3 times the mean cost of those with only medical use of opioids or those who abused, but did not tamper. Presenteeism costs were highest among non-tampering abusers at $2,276; this estimate was 3 times the average costs incurred by non-opioid controls and 38% higher than the costs associated with the use of opioids for medical use only. Presenteeism costs between respondents...
Table 2 Demographic and health characteristics of the sample

<table>
<thead>
<tr>
<th>Use of prescription opioids</th>
<th>NHWS</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current survey (N=1,206)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abuse with tampering (n=107)</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>Medical use only (n=981)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-opioid control (n=19,679)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Demographics
- **Age, years (mean, SD)**: 36.51 (11.97), 39.77 (11.96), 52.21 (15.61), 50.42 (15.83)
- **Female**: 44.9 (48), 51.7 (61), 57.2 (561), 58.0 (11415)
- **Race/ethnicity**
  - **White**: 41.1 (44), 58.5 (69), 80.2 (787), 80.1 (15762)
  - **Black**: 16.8 (18), 11.9 (14), 9.2 (90), 8.1 (1587)
  - **Hispanic**: 20.6 (22), 15.3 (18), 4.7 (46), 5.1 (996)
  - **Asian**: 20.6 (22), 22.0 (26), 28.0 (33), 31.0 (33)
  - **Other**: 0.9 (1), 2.5 (3), 2.8 (27), 2.2 (43)
- **BMI categories**
  - **Underweight**: 4.7 (5), 1.7 (2), 1.6 (16), 1.9 (379)
  - **Normal**: 46.7 (50), 40.7 (48), 26.8 (263), 31.9 (6274)
  - **Overweight**: 28.0 (30), 26.3 (31), 27.5 (270), 32.2 (6331)
  - **Obese**: 18.7 (20), 30.5 (36), 42.3 (415), 31.8 (6252)
  - **BMI control**: 1.9 (2), 0.8 (1), 1.7 (17), 2.3 (443)
  - **CCI (mean, SD)**: 0.4 (1.11), 0.28 (0.77), 0.76 (1.33), 0.34 (0.85)
  - **Absence**: >2 times/week: 80.4 (86), 41.5 (49), 0.0 (0), 0.0 (0)

Notes: Thirty-six of the 1,242 respondents were excluded for unintelligible open-ended responses (n=8) or tampered with the medication but did not report abuse (n=28).

BMI, body mass index; CCI, Charlson Comorbidity Index; NHWS, National Health and Wellness Survey.

Table 3 Estimated 3-month indirect costs by use of prescription opioids

<table>
<thead>
<tr>
<th>Use of prescription opioids</th>
<th>NHWS</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current survey (N=1,206)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abuse with tampering (n=81)</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>Medical use only (n=433)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-opioid control (n=10,922)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes**: Sample size is reduced as analysis restricted to employed respondents not on vacation the week prior to survey; means in the same row that do not share the same subscript letter (a–d) are different at p<0.05 using the Fisher’s LSD test. Thirty-six of the 1,242 respondents were excluded for unintelligible open-ended responses (n=8) or tampered with the medication but did not report abuse (n=28).

**Abbreviations**: LSD, least significant difference; NHWS, National Health and Wellness Survey.
who abused did not differ according to tampering. When absenteeism and presenteeism costs were combined, these total costs were significantly higher with tampering abuse $3,614 than non-tampering abuse, which were the next most expensive group. Median costs were generally consistent with the pattern of means. Notably, those who tampered were the only group with a median absenteeism cost above zero, and median indirect costs were 44% higher among those who abused and tampered relative to those who abused but did not tamper.

Direct costs were elevated in those who abused and tampered relative to all other groups for all of the comparisons, including physician visit costs, ER costs, hospitalizations, and drug rehabilitation ($p<0.05; Table 4). Mean direct costs due to non-opioid-related health care resource use were $14,180, ~6 times that of the next most expensive group (non-tampering abuse, $2,236), for an incremental cost of $11,944. The difference in costs was also significant for each type of service individually. Mean direct costs for opioid-related utilization were likewise elevated in those who abused and tampered, estimated at $8,790, ~4 times the cost of those who abused but did not tamper ($2,223, $p<0.05), for an incremental cost of $6,567. When considered as total costs, those who abused and tampered incurred an estimated $23,328 in direct medical expenses during the 3-month period, while non-tampering abusers incurred $4,514, and non-abusing opioid users incurred $3,248 (for all, $p<0.05), for an unadjusted incremental cost of $18,814 for abuse with tampering relative to abuse without tampering. All of these costs were greatly elevated relative to the $495 estimated for the control group (for all, $p<0.05). Furthermore, the pattern was not driven wholly by outliers. Even after excluding any extreme responses, the group who tampered and abused was the only one to have non-zero costs for opioid-related care and drug rehabilitation, and these respondents also had the highest median costs for non-opioid-related care.

Adjusted indirect costs were not significantly higher among those who abused and tampered with the medication ($3,361) than among those who abused without tampering ($2,566; $p=0.17). As in the unadjusted comparisons, the regression modeling indicated higher direct costs associated with tampering (Figure 2). All-cause direct costs were more than 6 times as high among those who tampered as those who abused but did not tamper ($20,289 for those who tampered vs $2,971 for those who did not, $p<0.001; Figure 2). Likewise, the adjusted opioid-specific direct costs were almost 5 times as high among those who tampered relative to those who did not ($6,887 vs $1,454, $p<0.001).

Table 4

<table>
<thead>
<tr>
<th>Use of prescription opioids</th>
<th>Current survey (N=1,206)*</th>
<th>Abuse with tampering (n=107)</th>
<th>Abuse without tampering (n=118)</th>
<th>Medical use only (n=981)</th>
<th>NHWS (n=19,679)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-opioid related</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physician</td>
<td>$545_2$</td>
<td>$891$</td>
<td>$108$</td>
<td>$217_4$</td>
<td>$396$</td>
</tr>
<tr>
<td>ER</td>
<td>$708_8$</td>
<td>$1,164$</td>
<td>$0$</td>
<td>$173_8$</td>
<td>$394$</td>
</tr>
<tr>
<td>Hospitalization</td>
<td>$12,927_4$</td>
<td>$31,244$</td>
<td>$0$</td>
<td>$1,846$</td>
<td>$5,924$</td>
</tr>
<tr>
<td>Total</td>
<td>$14,180_4$</td>
<td>$32,245$</td>
<td>$553$</td>
<td>$2,236$</td>
<td>$6,433$</td>
</tr>
<tr>
<td>Opioid-related</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physician</td>
<td>$693_4$</td>
<td>$1,084$</td>
<td>$232$</td>
<td>$163_4$</td>
<td>$502$</td>
</tr>
<tr>
<td>ER</td>
<td>$870_8$</td>
<td>$1,346$</td>
<td>$633$</td>
<td>$290_8$</td>
<td>$2,121$</td>
</tr>
<tr>
<td>Hospitalization</td>
<td>$7,227_4$</td>
<td>$11,881$</td>
<td>$0$</td>
<td>$1,770_4$</td>
<td>$4,022$</td>
</tr>
<tr>
<td>Total</td>
<td>$8,790_4$</td>
<td>$13,546$</td>
<td>$1,679$</td>
<td>$2,223_4$</td>
<td>$4,813$</td>
</tr>
<tr>
<td>Overall (non-opioid related + opioid related)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physician</td>
<td>$1,238_8$</td>
<td>$1,904$</td>
<td>$448$</td>
<td>$380_8$</td>
<td>$790$</td>
</tr>
<tr>
<td>ER</td>
<td>$1,578_8$</td>
<td>$2,339$</td>
<td>$633$</td>
<td>$463_8$</td>
<td>$2,166$</td>
</tr>
<tr>
<td>Hospitalization</td>
<td>$20,155_9$</td>
<td>$38,602$</td>
<td>$0$</td>
<td>$3,616_8$</td>
<td>$9,141$</td>
</tr>
<tr>
<td>Drug rehabilitation</td>
<td>$358,578$</td>
<td>$49$</td>
<td>$49$</td>
<td>$55_4$</td>
<td>$204$</td>
</tr>
<tr>
<td>Overall total</td>
<td>$23,328_4$</td>
<td>$41,672$</td>
<td>$4,019$</td>
<td>$4,514_4$</td>
<td>$10,434$</td>
</tr>
</tbody>
</table>

Notes: Means in the same row that do not share the same subscript letter (a–d) are different at $p<0.05$ using the Fisher’s LSD test. *Thirty-six of the 1,242 respondents were excluded for unintelligible open-ended responses (n=8) or tampered with the medication but did not report abuse (n=28). Non-opioid control data are from NHWS, which do not allow for differentiation of opioid-related costs.

Abbreviations: ER, emergency room; LSD, least significant difference; NHWS, National Health and Wellness Survey.
Discussion

This study surveyed a large sample of US adults with self-reported opioid medication use to provide per-patient estimates of the economic burden of opioid medication abuse with and without tampering. In line with prior work, individuals who abused opioid medications had substantially increased costs relative to non-abusers, including individuals using opioid medications for their intended medical purposes and control subjects. Moreover, abuse with tampering was associated with substantially higher costs than abuse without tampering. This finding remained consistent after adjusting for relevant covariates.

Chronic opioid abusers who reported tampering with medications were estimated to have the highest costs. Regarding the workforce, those who abused and tampered reported higher mean absenteeism costs, relative to all other groups. Mean costs for work missed (absenteeism) were over $1,800 – nearly 3 times higher than those who abused without tampering, more than 3 times higher than those using opioids for their intended medical purpose, and ~10 times higher than controls. Presenteeism costs were more similar between the two groups who abused and the group using opioids for their intended medical purpose, though it is important to keep in mind that high absenteeism places a limit on presenteeism costs as the time spent impaired at work is limited by the time completely away from work. When total indirect costs were considered, these were highest among those who abused and tampered. Direct costs were higher than indirect costs, and those who abused and tampered incurred an average of over $23,000 in estimated direct medical costs for both opioid-related health care and non-opioid-related health care. These costs were over 5 times greater than those incurred by respondents who abused without tampering. Notably, opioid-specific medical costs in those who abused and tampered were nearly quadruple those of respondents who abused, but did not tamper which represented an increase of ~$6,500.

Regression modeling among opioid abusers showed a similar pattern of results, although indirect costs were not significantly higher among those who abused and tampered relative to those who did not tamper. Adjusted all-cause direct costs were more than 6 times as high among those who abused and tampered as those who abused but did not tamper (> $20,000 vs $3,000). Though respondents attributed most of their medical care to non-opioid-related health problems, costs estimated from opioid-specific medical visits were at nearly $7,000 per quarter, almost 5 times as high among those who abused and tampered relative to those who abused but did not tamper.

These data also show a strong connection between tampering and frequency, with those who abused more frequently being more likely to tamper with the medication. The connection between frequency and tampering should not be a surprise as tampering increases the number of ways in which a drug can potentially be abused. Both increased frequency and tampering are likely to be markers of more advanced.
longer-term abuse or dependence. We chose not to try to disentangle tampering from abuse frequency, but it is likely that some of the differences between the two abusing groups would remain even if tampering was eliminated.

To our knowledge, this is the first study to provide per-patient estimates of the US economic burden of medical opioid abuse according to whether or not the medication was tampered with. These data provide an impetus to focus special efforts on attenuating abuse among those tampering with opioids, and go beyond earlier analysis describing work impairment and health care use. Estimating costs not only allows the magnitude of tampering with prescription opioid medication to be more easily compared with other public health priorities but also allows for impacts of work impairment and disparate types of health care – which cannot otherwise be integrated – to be combined into a single, understandable metric.

Limitations

There are limitations to the current study inherent to cross-sectional, self-reported data. First, opioid use and abuse were self-reported and retrospective and therefore subject to the errors of recall. The results are specific to the definition of abuse adopted for this study, which is narrower here than the NMU often equated with abuse.14 Lost work productivity and medical visits were also self-reported, and recall bias may have resulted in over or underestimation. Recall errors may be more pronounced among those who are abusing prescription opioids and frequently accessing medical care. Second, indirect cost estimates were based on average wages, which may not have been representative of the individuals included in the study, and estimates of direct costs were based on average unit costs rather than actual expenses. Third, the data are cross-sectional and, as such, no claims about cause and effect are possible. However, it seems very unlikely that tampering with opioids would be an effect of health care use and work impairment instead of a cause. Finally, it is important to note the lack of data on respondents indicating opioid misuse in the current survey. The screening for the current study required respondents to report taking opioids according to their physician’s directions (medical use only group), and/or using the opioid to get high (abuse groups). Respondents to the screener who abused according to whether or not the medication was tampered and, as such, no claims about cause and effect are possible. It is possible that variables aside from tampering would explain some differences in costs between those who do and do not tamper. While some potential confounders were controlled for using regression, there could be other unmeasured variables that account for some of the observed differences in outcomes. As already noted above, those who tampered were overwhelmingly frequent abusers of prescription opioids, and no attempt was made to control for frequency in the regression models. We should also note that analyses were repeated using alternative sources of unit costs, and these confirmed the significant relationship between tampering and direct medical costs (data available from the corresponding author). Notably, the present study did not collect information on abuse of other drugs, but individuals who abuse prescription opioids through tampering may be more likely to abuse other drugs as well. If so, some of the incremental cost of tampering would likely be attributable to abuse of other drugs if non-opioid drug abuse was more common and/or more severe among those who tampered with prescription opioids. This is an important point when considering whether to invest in interventions to combat opioid tampering, whether through education, prescribing other types of analgesics, or abuse-deterrent formulations of opioids. However, the magnitude of the elevated costs among those who abused and tampered with prescription opioids relative to those who abused without tampering argue for continued research to reduce the impact of opioid abuse.

Conclusion

Ultimately, study results indicate opioid abuse to be associated with significant economic costs, and this is particularly true when individuals tamper with the medication. In light of the findings from this study, measures to prevent or reduce the incidence of opioid tampering may help to reduce the substantial impact of opioid abuse on the workforce and health care systems. Policymakers and practitioners should consider the high cost per tampering individual when evaluating such measures.

Acknowledgments

This study was sponsored by Pfizer. Editorial/medical writing support was provided by Tammy Schuler and Martine C. Maculaitis at Kantar Health and was funded by Pfizer. These results were presented as a poster at the 2015 International Meeting of the International Society of Pharmacoeconomics and Outcomes Research in Philadelphia, Pennsylvania, in June 2015. The abstract for that presentation was published as: Cost of tampering in abuse of prescription opioids. *Value Health*. 2015;18(3):A120.

Disclosure

Jeffrey Vietri was an employee of Kantar Health during the development of this paper, Kantar Health are paid consultants to Pfizer in connection with this study and the development...
of this paper. Jeffrey Vietri, Elizabeth Masters, Alexandra Barsdorf, and Jack Mardekian are employees of and hold stock options for Pfizer. The authors report no other conflicts of interest in this work.

References


3. Centers for Disease Control and Prevention, Center for Behavioral Health Statistics and Quality. Results from the 2013 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD, USA: SAMHSA; 2014.


